A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)
Autor: | Eva Gonczol, Zsofia Gyulai, Klara Berencsi, Stuart P. Adler, Pierre Dellamonica, Jian Ben Wang, John M. Zahradnik, William I. Cox, Al M. Best, Stanley A. Plotkin, Steve Pincus, Claude Meric, Michel Cadoz |
---|---|
Rok vydání: | 1999 |
Předmět: |
Adult
Male Human cytomegalovirus Genetic Vectors Cytomegalovirus Canarypox Vector Enzyme-Linked Immunosorbent Assay Canarypox virus Antibodies Viral Vaccines Attenuated Avipoxvirus Double-Blind Method Viral Envelope Proteins Betaherpesvirinae medicine Humans Immunology and Allergy biology Immunogenicity virus diseases Viral Vaccines Middle Aged biology.organism_classification medicine.disease Virology Infectious Diseases Antibody Formation Cytomegalovirus Infections Immunology biology.protein Female Antibody Cytomegalovirus vaccine medicine.drug |
Zdroj: | The Journal of Infectious Diseases. 180:843-846 |
ISSN: | 1537-6613 0022-1899 |
Popis: | To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies. |
Databáze: | OpenAIRE |
Externí odkaz: |